Total medical devices industry deals for May 2019 worth $9.1bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 547% over the previous month and a rise of 122.04% when compared with the last 12-month average of $4.1bn.

In terms of number of deals, the sector saw a rise of 12.7% over the last 12-month average with 124 deals against the average of 110 deals.

In value terms, North America led the activity with deals worth $8.23bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Medical devices industry deals in May 2019: Top deals

The top five medical devices deals accounted for 86.9% of the overall value during May 2019.

The combined value of the top five medical devices deals stood at $7.9bn, against the overall value of $9.1bn recorded for the month. The top announced medical devices deal tracked by GlobalData in May 2019 was 3M‘s $6.73bn acquisition of Acelity.

In second place was the $465m acquisition of VertiFlex by Boston Scientific and in third place was Ethicon US’s $400m asset transaction with Takeda Pharmaceutical.

The $200m venture financing of MGI Tech by Gold Stone Investment, Green Pine Capital Partners and Shanghai Orient Securities Capital Investment and Biomatics Capital Partners, BlueCross BlueShield Venture Partners, Camden Partners Holdings, Casdin Capital, Cowin Venture Capital, Exact Sciences, Gamma3, Section 32, Invus Group and Third Rock Ventures’ venture financing of Thrive Earlier Detection for $110m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.